A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: LY3437943

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03841630

17136

J1I-MC-GZBA (Other Identifier)

Details and patient eligibility

About

This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3437943 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Enrollment

45 patients

Sex

All

Ages

21 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Overtly healthy male or a female who cannot get pregnant
Have a body mass index (BMI) between 19 and 40 kilograms per square meter (kg/m²), inclusive, at screening
Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
Have veins suitable for ease of blood sampling

Exclusion criteria

Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
Have previously completed or withdrawn from this study
Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking during the inpatient stay in the study
Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
Have been treated with weight loss medications within 3 months of screening